Latest news with #BioconBiologics
BusinessToday
2 days ago
- Health
- BusinessToday
Biocon Surpasses 100 Million Insulin Cartridges Supplied To MOH
Biocon Biologics Ltd's Malaysian arm, Biocon Sdn Bhd has crossed a major milestone by supplying over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health since 2016, benefitting more than 345,000 diabetes patients nationwide. The insulin is produced at Biocon's state-of-the-art manufacturing facility in Johor, established with a cumulative investment of US$600 million. Recognised by the Malaysia Book of Records as the first and largest integrated insulin manufacturer in the country, the plant produces a wide range of insulins in various delivery forms. 'Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes,' said Biocon Biologics Chief Commercial Officer Susheel Umesh. Biocon Biologics' longstanding partnership with the Ministry of Health and Duopharma Marketing Sdn. Bhd. aims to advance insulin access and healthcare resilience. Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, reaffirmed this, stating the collaboration is focused on delivering affordable, high-quality insulin to Malaysians. Globally, Biocon Biologics is ranked among the top three producers of rh-insulin and Insulin Glargine, having delivered 9.2 billion doses to date. Related
Business Standard
2 days ago
- Business
- Business Standard
Biocon Biologics expands access to insulin in Malaysia
Supplies over 100 million cartridges of recombinant human insulin to Malaysia's Ministry of Health Biocon Biologics (BBL) announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the milestone of supplying 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health (MoH). This achievement reinforces Biocon Biologics' long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country. Since entering the Malaysian market in 2016, Biocon Biologics has played a pivotal role in transforming diabetes management, and has supplied over 100 million cartridges of rh-insulin serving over 345,000 patients. Biocon Biologics' public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem by driving innovation, developing local talent, enabling better patient outcomes and advancing insulin self sufficiency in Malaysia.
Business Upturn
2 days ago
- Business
- Business Upturn
Biocon Biologics crosses 100 million insulin cartridge deliveries in Malaysia
By Aman Shukla Published on June 30, 2025, 08:56 IST Biocon Biologics Ltd. (BBL), through its Malaysian arm Biocon Sdn. Bhd., has delivered over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health (MoH). The company has been supplying insulin to Malaysia since 2016, supporting diabetes management efforts across the country. As part of a long-standing public-private partnership with the Malaysian government, Biocon Biologics has helped serve around 345,000 patients by making rh-insulin more accessible. The collaboration is aimed at supporting local healthcare needs through stable supply and improved access to affordable insulin therapy. The company's insulin manufacturing facility in Johor, established with a cumulative investment of $600 million since 2011, functions as a Center of Excellence (CoE) for insulin production. The facility is equipped to manufacture various types of insulin—regular, basal, and rapid-acting—in formats such as cartridges and delivery devices. The site has been acknowledged by the Malaysia Book of Records as the country's first and largest integrated insulin manufacturer. Globally, Biocon Biologics has distributed over 9.2 billion doses of rh-Insulin and Insulin Glargine to patients, as part of its wider effort to support insulin access worldwide. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
4 days ago
- Business
- Business Standard
Biocon's biologics arm gets Health Canada approval for aflibercept biosimilar 'Yesafili'
Biocon said that its subsidiary Biocon Biologics has received a notice of compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, from Health Canada. This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor. It is prescribed for the treatment of several eye conditions. These include neovascular (wet) age-related macular degeneration (AMD). It also treats visual impairment caused by macular edema secondary to central retinal vein vein occlusion (CRVO). Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) is another indication. Furthermore, it is used for diabetic macular edema (DME). It also treats myopic choroidal neovascularization (myopic CNV). The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, confirming that YESAFILI is highly similar with no clinically meaningful differences to EYLEA in terms of quality, safety, and efficacy. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: The approval of YESAFILI by Health Canadathe first biosimilar to EYLEA in Canadais a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch YESAFILI, making it our 10th biosimilar to be commercialized worldwide. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. The companys consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.96% to currently trade at Rs 353.90 on the BSE.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Biocon Biologics to launch Eylea biosimilar Yesafili in Canada next month
Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from Health Canada for Yesafili (aflibercept), a biosimilar to Eylea, marking the first such approval for an Eylea biosimilar in the country. The authorisation, granted via a Notice of Compliance (NOC), covers both vial and prefilled syringe formats (2 mg/0.05 mL). Yesafili is set to launch in Canada on July 4. Shreehas Tambe, chief executive officer and managing director, Biocon Biologics, said: 'The approval of Yesafili by Health Canada—the first biosimilar to Eylea in Canada—is a proud moment for Biocon Biologics. We are excited that in July, Canada will be the first country where we will launch Yesafili, making it our 10th biosimilar to be commercialised worldwide. This milestone reflects our science-driven innovation, global commercialisation strength and continued commitment to expanding access to high-quality, affordable biologics for patients across the globe.' Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for treating several retinal conditions that cause visual impairment. These include neovascular (wet) age-related macular degeneration (AMD), macular oedema resulting from central or branch retinal vein occlusion (CRVO and BRVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV). Furthermore, the company said the approval is based on a comprehensive package of analytical, nonclinical and clinical data, confirming that Yesafili is highly similar with no clinically meaningful differences to Eylea regarding quality, safety and efficacy. In April this year, Yesafili received approval for launch in the United States. In May 2024, the US Food and Drug Administration approved Yesafili.
